Log in

Relevant bibliographies by topics / Cyfra 21-1

Contents

Journal articles
Dissertations / Theses
Book chapters
Conference papers

Academic literature on the topic 'Cyfra 21-1'

Author: Grafiati

Published: 4 June 2021

Last updated: 5 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cyfra 21-1.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cyfra 21-1"

1

Boutten, Anne. "CYFRA 21-1." EMC - Biologie Médicale 1, no. 1 (January 2006): 1–2. http://dx.doi.org/10.1016/s2211-9698(06)76055-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ohlendorf, D., G. M. Oremek, and D. A. Groneberg. "Cyfra 21-1." Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie 67, no. 4 (June 22, 2017): 224–25. http://dx.doi.org/10.1007/s40664-017-0194-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Song, Keum-Soo, Satish Balasaheb Nimse, Shrikant Dashrath Warkad, Ae-Chin Oh, Taisun Kim, and Young Jun Hong. "Correction: Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer." Chemical Communications 55, no. 73 (2019): 10984. http://dx.doi.org/10.1039/c9cc90396h.

Full text

Abstract:

Correction for ‘Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer’ by Keum-Soo Song et al., Chem. Commun., 2019, 55, 10060–10063.

APA, Harvard, Vancouver, ISO, and other styles

4

Zhang, Zhen, Chenglin Tian, Qiang Shi, Jing Hao, Na Zhao, and Zhijie Liu. "Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis." Disease Markers 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/2467870.

Full text

Abstract:

Cerebrospinal fluid (CSF) cytology has low sensitivity for leptomeningeal metastasis (LM); thus, new markers are needed to improve the diagnostic accuracy of LM. We measured carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA 21-1) in paired samples of CSF and serum from patients with LM and patients with nonmalignant neurological diseases (NMNDs) as controls. Receiver operating curve analysis was performed to assess their diagnostic accuracy for LM. In patients with NMNDs, CEA and CYFRA 21-1 levels in the CSF were significantly lower than the serum levels. In patients with LM, there was no significant difference between the CSF and serum CEA levels, whereas the CYFRA 21-1 levels were significantly higher in the CSF than the serum. CSF/serum quotients of CYFRA 21-1 were higher than those of CEA in patients with LM and patients with NMNDs. CSF CYFRA 21-1 and CSF/serum quotient of CYFRA 21-1 had high accuracy for differentiating LM from NMNDs that was similar to CSF CEA and CSF/serum quotient of CYFRA 21-1, whereas serum CYFRA 21-1 is of poor diagnostic value. Measurement of CSF CYFRA 21-1 should not be overlooked in patients with suspected LM, even if the serum CYFRA 21-1 level is within normal limits.

APA, Harvard, Vancouver, ISO, and other styles

5

Song, Keum-Soo, Satish Balasaheb Nimse, Shrikant Dashrath Warkad, Ae-Chin Oh, Taisun Kim, and Young Jun Hong. "Quantification of CYFRA 21-1 and a CYFRA 21-1–anti-CYFRA 21-1 autoantibody immune complex for detection of early stage lung cancer." Chemical Communications 55, no. 68 (2019): 10060–63. http://dx.doi.org/10.1039/c9cc03620b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rashid, H., S. Hossain, R. K. Chowdhury, S. Rahman, and M. M. Khan. "Role of Serum CYFRA 21-1 in the Diagnosis of Primary Lung Cancer." Journal of Medical Science & Research 27, Number 2 (July 1, 2017): 13–18. http://dx.doi.org/10.47648/jmsr.2017.v2702.03.

Full text

Abstract:

Majority of the lung cancer occurs in developing countries. In case of Bangladesh it's a burden for health in both serest. A definitive diagnosis of lung cancer can help the surgeons and physicians for making decisions about the plan of treatment. The rapidity of diagnosis also alleviates the patient's anxiety whether the lesion is nonmalignant or malignant Several studies proposed the role of CYFRA 21-1 level in diagnosis of lung cancer and its better management. To find the sensitive, feasible and cost effective test for detection of lung cancer and to evaluate the CYFRA 21-1 with their histopathological findings. This case control study was carried out in the department of Medicine of National Institute of Diseases of the Chest and Hospital (NIDCH) Dhaka and Enam Medical College Hospital, Savar, Dhaka during the period from January 2017 to September 2017. We included a total of 80 subjects among them 40 diagnosed cases of lung cancer and 40 controls with diseases other than lung cancer. The mean normal (< 3.5) serum CYFRA 21-1 level was (Mean *SD) 1.10 t 1.5 with ranging from 0.87 ng /ml — 1.5 ng lint Normal level of CYFRA 21-1 was found in all 40 (100%) of controls. The mean of high (> 3.5) serum CYFRA 21-1 level was (Mean +-SD) 18.20 ± 13.63 with rangingfrom 6.9 ng hnl — 49.30 ng/ml. High level of CYFRA 21-1 level was found in maximum 35(87.5%) cases. High (> 3.5 rig/m1) serum CYFRA 21-1 level was found maximum in squamous cell carcinoma (20), next adenocarcinoma (15). Among 40 cases diagnosed as malignant by histopathology, serum CYFRA 21-1 level was compared with histopathological findings. The sensitivity of serum CYFRA 21-1 level in case of squamous cell carcinoma, adenocarcinoma and combined were 90.90%, 83.33% and 87.5% respectively. The sensitivity and accuracy of serum CYFRA 21-1 for squamous cell carcinoma was more than that of adenocarcinoma. So serum CYFRA 21-1 level was highly sensitive for squamous cell carcinoma.

APA, Harvard, Vancouver, ISO, and other styles

7

Szturmowicz, M., A. Sakowicz, P. Rudzinski, J. Zych, E. Wiatr, J. Zalęska, and E. Rowinska-Zakrzewska. "The Clinical Value of Cyfra 21-1 Estimation for Lung Cancer Patients." International Journal of Biological Markers 11, no. 3 (July 1996): 172–77. http://dx.doi.org/10.1177/172460089601100306.

Full text

Abstract:

Cytokeratin-19, one of the cytoskeletal proteins, is expressed both in bronchial epithelium and in lung cancer cells. The aim of our study was to establish the value of serum cytokeratin-19 soluble fragment (Cyfra 21-1) measurement in lung cancer patients. Cyfra 21-1 levels were estimated in 35 patients (pts) with benign lung diseases and in 116 lung cancer patients: 55 pts with squamous cell lung cancer, 38 pts with small cell lung cancer and 23 pts with adenocarcinoma. The cutoff level was set at 4 ng/ml with a specificity of 94% and a sensitivity of 40%. Elevated Cyfra 21-1 values were found in 44% of squamous cell lung cancer, 39% of adenocarcinoma and 34% of small cell lung cancer pts (the difference was not significant). In squamous cell lung cancer and in adenocarcinoma elevated Cyfra 21-1 values were observed more often in patients with advanced disease than in patients with limited disease. There was no significant correlation between the initial Cyfra 21-1 level and the response to chemotherapy. Cyfra 21-1 was hot a prognostic indicator, although in operable squamous cell lung cancer the proportion of survivors in the second year of observation was higher among the patients with normal preoperative Cyfra 21-1 levels.

APA, Harvard, Vancouver, ISO, and other styles

8

Kim, Jung Hoon, Joon Cheol Song, Jung Hyun Kwon, Dae Kyun Kim, Dong Wook Jekarl, Jeong Won Jang, and Young Chul Yoon. "CYFRA 21-1 as a novel diagnostic serum biomarker in pancreatic cancer." Journal of Clinical Oncology 32, no. 3_suppl (January 20, 2014): 191. http://dx.doi.org/10.1200/jco.2014.32.3_suppl.191.

Full text

Abstract:

191 Background: CYFRA 21-1 is a fragment of cytokeratin 19, a structure protein and part of intermediate filament proteins contributing to stability of epithelial cells. Serum concentration of CYFRA 21-1 is known to be elevated in many types of epithelial malignancies, and especially it has a prognostic and predictive value in patients with non-small cell lung cancer. We assessed serum CYFRA 21-1 and studied its clinical significance in patients with pancreatic cancer. Methods: The sera from 52 patients diagnosed with pancreatic cancer was collected between May 2012 and August 2013 at Incheon St. Mary’s hospital, Catholic University of Korea, School of Medicine and was measured for CYFRA 21-1 and CA 19-9. 48 patients had an advanced disease at presentation, 2 patients had a locally advanced disease, and 2 patients presented with a local disease. Control blood samples were obtained from 31 healthy individuals and 48 patients with nonmalignant hepatic or pancreatobiliary disease. We measured CYFRA 21-1 using two-step sandwich, chemiluminescent microparticle immunoassay, Architect i2000SR (Abbott Laboratories, Ltd., Il, USA). Results: Serum concentration of CYFRA 21-1 was significantly elevated in patients with pancreatic cancer compared with control group. (p=.000) CYFRA 21-1 ( >1.96 ng/ml as determined by the ROC curve) had a sensitivity, specificity, positive predictive value, and negative predictive value of 86.5%, 79.7%, 73.8%, 90% for the diagnosis of pancreatic cancer. Additionally, CA 19-9 ( >35 U/ml determined by our institute’s criteria) had a sensitivity, specificity, positive predictive value, and negative predictive value of 67.3%, 89.9%, 69.1%, 81.6%. The area under curve for CYFRA 21-1 and CA 19-9 was 86.3% and 81.5%, respectively. Conclusions: CYFRA 21-1 has a potential to become a novel serum biomarker for the diagnosis of pancreatic cancer. Serum concentration of CYFRA 21-1 in combination with CA 19-9 can be useful in clinical practice to diagnose pancreatic cancer.

APA, Harvard, Vancouver, ISO, and other styles

9

Deng, Yan Fei, Ping Chen, Yong Zhi Lin, Jia Zhen Le, Xiao Li Wu, Ming Qiang Yu, Pei Yun Zhuang, and Ming Hua Gao. "Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma." Journal of Laryngology & Otology 117, no. 3 (March 2003): 190–94. http://dx.doi.org/10.1258/002221503321192485.

Full text

Abstract:

This paper attempts to evaluate the clinical usefulness of CYFRA 21-1 as a serum tumour marker in patients with head and neck squamous cell carcinoma (HNSCC).The serum concentration of CYFRA 21-1 was measured utilizing a new electrochemiluminescent immunoassay (ECLIA) in 142 patients with HNSCC before and after treatment, 68 patients with benign tumours of the head and neck, and 50 healthy controls.Serum levels of CYFRA 21-1 in patients with HNSCC were significantly higher than those of benign tumours and healthy controls (p < 0.001). The diagnostic sensitivity and specificity of CYFRA 21-1 for HNSCC were 62 per cent and 100 per cent, respectively. The positive rates of CYFRA 21-1 increased with progression of HNSCC, serum CYFRA 21-1 levels were related to the tumour stage expressed by primary tumour (T) and nodal status (N) (p < 0.001), but not related to patient age, gender, smoking and drinking habit, or histopathological grade (p > 0.05). Post-treatment levels of CYFRA 21-1 in HNSCC decreased significantly (p < 0.001). Among 38 patients with clinical or radiological evidence of a recurrence during follow-up, 78.9 per cent (30 of 38) showed an increase in CYFRA 21-1.The analytical ECLIA performance for serum CYFRA 21-1 provides a new means of clinical assessment for HNSCC. The results of ECLIA suggest that the serum marker CYFRA 21-1 is valuable not only for diagnosis but also for close monitoring of patients with HNSCC.

APA, Harvard, Vancouver, ISO, and other styles

10

Gadducci, A., M. Ferdeghini, S. Cosio, A. Fanucchi, R. Cristofani, and A. R. Genazzani. "The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer." International Journal of Gynecologic Cancer 11, no. 4 (2001): 277–82. http://dx.doi.org/10.1136/ijgc-00009577-200107000-00004.

Full text

Abstract:

Abstract.Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R, Genazzani AR. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.CYFRA 21-1 assay, which detects serum fragments of cytokeratin 19, has been widely assessed as a serum marker of several malignancies. Preoperative serum CYFRA 21-1 levels were retrospectively measured in 60 patients with ovarian cancer and in 59 control patients with benign ovarian disease. CYFRA 21-1 levels were also serially measured in 90 serum samples drawn from patients with advanced (FIGO stage III-IV) ovarian cancer followed after surgery and chemotherapy. Preoperative serum CYFRA 21-1 levels were higher in patients with ovarian cancer compared with controls (median, range = 2.6, 0.1–51.4 ng/ml versus 0.4, 0.0–3.6 ng/ml, P < 0.0001), and among the former, antigen values were higher in the 39 patients with advanced-stage than in the 21 patients with early (FIGO stage I-II) disease (P < 0.0001). In advanced ovarian cancer patients, the 25%, 50%, and 75% quantiles of preoperative CYFRA 21-1 levels were 1.9, 4.8 and 14.4 ng/ml, respectively. Preoperative CYFRA 21-1 levels were lower in the 11 patients who achieved a pathologic complete response at second-look compared with those who had clinically or surgically detectable persistent disease after first-line chemotherapy (median, range 1.9, 0.6–9.2 ng/ml versus 10.2, 0.1–51.4 ng/ml, P = 0.007). The pathologic complete response rate was significantly greater in patients with low preoperative CYFRA 21-1 levels compared with those with elevated CYFRA 21-1 levels at any cut-off limit for the antigen (1.9, 4.8 and 14.4 ng/ml). However, Cox regression analysis failed to detect a significant association between preoperative CYFRA 21-1 assay and survival. As for the follow-up of advanced ovarian cancer patients, CYFRA 21-1 levels were higher in the 42 samples drawn from patients with clinically detectable disease compared with the 48 specimens collected from patients with no clinical evidence of disease (median, range = 1.15, 0.3–40.7 ng/ml versus 0.4, 0.1–9.1 ng/ml, P < 0.0001). In conclusion, preoperative serum CYFRA 21-1 assay appears to be predictive of response to chemotherapy, but not prognostic of survival, for patients with advanced ovarian cancer. Moreover, the serial measurement of CYFRA 21-1 levels might have a potential clinical relevance for the assessment of disease status in patients followed after surgery and chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Cyfra 21-1"

1

Coulhon, Marie-Pierre. "Cyfra 21-1 et tumeurs épidermoi͏̈des ORL." Paris 5, 1997. http://www.theses.fr/1997PA05P097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gruber, Christine. "Differentialdiagnose beim Lungenkarzinom durch CEA, CYFRA 21-1, NSE und ProGRP." Diss., lmu, 2008. http://nbn-resolving.de/urn:nbn:de:bvb:19-90260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Soyeur, Luc. "Les marqueurs urinaires des tumeurs urothéliales : place du CYFRA 21-1." Bordeaux 2, 2001. http://www.theses.fr/2001BOR23021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Janvier, Pierre-Laurent. "Le cyfra 21-1 : un nouveau marqueur tumoral dans les cancers broncho-pulmonaires." Bordeaux 2, 1994. http://www.theses.fr/1994BOR23044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ramakers, Michel. "Intérêt du dosage du cyfra 21. 1 dans les cancers bronchiques : étude portant sur 80 dossiers." Caen, 1994. http://www.theses.fr/1994CAEN3082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Céruse, Philippe. "Intérêt d'un nouveau marqueur tumoral sérique le Cyfra 21-1 dans les carcinomes des voies aéro-digestives supérieures." Lyon 1, 2003. http://www.theses.fr/2003LYO1T188.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gruber, Christine Sigrid [Verfasser]. "Differentialdiagnose beim Lungenkarzinom durch CEA, CYFRA 21-1, NSE und ProGRP / vorgelegt von Christine Sigrid Gruber." 2008. http://d-nb.info/990840468/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Alkotyfan, Khaled [Verfasser]. "Cyfra 21-1 als Follow-up-Tumormarker bei Patienten mit Plattenepithelkarzinom des Oropharynx / vorgelegt von Khaled Alkotyfa." 2009. http://d-nb.info/999843508/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Al-Shagahin, Hani [Verfasser]. "Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma / vorgelegt von Hani Al-Shagahin." 2009. http://d-nb.info/1000244288/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cyfra 21-1"

1

Ebert, W., and P. Drings. "CYFRA 21-1 beim Bronchialkarzinom: Ergebnisse einer prospektiven Multicenterstudie." In Malignome und Hämostase, 107–22. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79744-6_11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Brockmann, J. G., H. St Nottberg, L. Biermann, and N. Senninger. "CYFRA 21-1 — Ein neuer Tumormarker für das ösophaguskarzinom." In Deutsche Gesellschaft für Chirurgie, 350. Berlin, Heidelberg: Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-642-55715-6_216.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Stieber, P., H. Dienemann, U. Hasholzner, P. G. Fabricius, C. Schambeck, M. Weinzierl, S. Poley, et al. "Vergleich von CYFRA 21-1, TPA und TPS beim Bronchialkarzinom, Blasenkarzinom und bei benignen Erkrankungen." In Malignome und Hämostase, 96–106. Berlin, Heidelberg: Springer Berlin Heidelberg, 1996. http://dx.doi.org/10.1007/978-3-642-79744-6_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

"CYFRA 21-1." In Springer Reference Medizin, 643. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_310931.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

"CYFRA 21-1." In Encyclopedia of Cancer, 1036. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_1441.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

"Cytokeratin 19 Fragments (CYFRA 21–1)." In Encyclopedia of Cancer, 1051. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_1471.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rameken, M., M. Bahlo, R. Klapdor, A. von Osten, A. Niendorf, and H. Bodenmüller. "Secretion Behavior of the Cytokeratin Marker Cyfra 21-1: Studies in Xenografts of Human Lung and Pancreatic Carcinomas Established in Nude Mice." In Contributions to Oncology, 90–95. S. Karger AG, 1996. http://dx.doi.org/10.1159/000425235.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cyfra 21-1"

1

Gehrt, F., SA Rudhart, U. Geisthoff, R. Birk, BA Stuck, S. Hoch, and K. Thangavelu. "Stellenwert des Tumormarkers CYFRA 21-1 im Rahmen der Behandlung fortgeschrittener Larynx- / Hypopharynxkarzinome." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1711591.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Gehrt, F., SA Rudhart, K. Thangavelu, UW Geisthoff, R. Birk, BA Stuck, and S. Hoch. "Stellenwert des Tumormarkers CYFRA 21-1 im Rahmen der Behandlung fortgeschrittener Larynx- / Hypopharynxkarzinome." In 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727858.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Hoch, S., S. Rudhart, BA Stuck, and R. Birk. "Stellenwert des Tumormarkers CYFRA 21 – 1 zur Beurteilung der regionären und distanten Tumorkontrolle fortgeschrittener Oropharynxkarzinome." In Abstract- und Posterband – 89. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Forschung heute – Zukunft morgen. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1640044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rudhart, SA, R. Birk, BA Stuck, and S. Hoch. "Stellenwert des Tumormarkers CYFRA 21 – 1 bei der Behandlung kutaner Plattenepithelkarzinome der Kopf- und Halsregion." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1685911.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Rudhart, SA, P. Langen, K. Thangavelu, U. Geisthoff, R. Birk, BA Stuck, and S. Hoch. "Stellenwert des Tumormarkers CYFRA 21-1 in der Behandlung fortgeschrittener Oropharynxkarzinome mittels Radio(chemo)therapie." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1711666.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Stock, CJW, R. Hoyles, C. D’accord, M. Kokosi, V. Alfieri, C. Campochiaro, J. Donovan, et al. "S143 Serum CYFRA 21–1 as a prognostic marker in scleroderma-associated interstitial lung disease." In British Thoracic Society Winter Meeting 2018, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 5 to 7 December 2018, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2018. http://dx.doi.org/10.1136/thorax-2018-212555.149.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Rudhart, SA, K. Thangavelu, F. Gehrt, UW Geisthoff, R. Birk, BA Stuck, and S. Hoch. "Stellenwert des Tumormarkers CYFRA 21-1 in der Behandlung fortgeschrittener Oropharynxkarzinome mittels Radio(chemo)therapie." In 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727866.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rudhart, SA, R. Birk, BA Stuck, and S. Hoch. "Significance of the tumor marker Cyfra 21 – 1 for head and neck cutaneous squamous cell carcinoma." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1686059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hamesch, K., N. Guldiken, M. Aly, N. Hueser, D. Hartmann, C. Trautwein, S. Mueller, et al. "Serum CYFRA 21 – 1 levels are elevated in advanced liver disease and associate with poor survival." In 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0038-1677127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Hoch, S., S. Rudhart, BA Stuck, and R. Birk. "Clinical impact of CYFRA 21 – 1 as a tumor marker for regional and distant tumor control in advanced oropharyngeal cancer." In Abstract- und Posterband – 89. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Forschung heute – Zukunft morgen. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1640045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!